Different treatments for Crohn's disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored [0.03%]
不同方法治疗克罗恩病合并重度急性下消化道出血：英夫利西单抗疗法至关重要不容忽视
Shuoyi Yao,Zheyu Wang,Mingyan Xie et al.
Shuoyi Yao et al.
Objective: Acute severe lower gastrointestinal bleeding (SLGIB) is one of the life-threatening complications of Crohn's disease (CD) whose therapy is being optimized constantly. We aim to evaluate the therapeutic efficaci...
Review of clinical advances in the procedural sedation application of remimazolam [0.03%]
瑞玛唑仑在镇静程序中的临床应用进展评述
Qiwei Wang,Shuancheng Bai
Qiwei Wang
Introduction: With the ongoing advancement of comfort-oriented healthcare, procedural sedation is increasingly applied in clinical practice. As a novel benzodiazepine derivative, remimazolam offers distinct advantages in ...
Chronic inflammation as a driving factor for sarcopenia: an update on pathophysiology and future therapeutic targets [0.03%]
慢性炎症促进肌肉减少症发病的病理生理机制及其未来治疗靶点的研究进展
Zihan Liang,Lin Zhang
Zihan Liang
Sarcopenia is a syndrome characterized by an age-related progressive decline in skeletal muscle mass, strength, and function. It represents a significant public health concern because of its adverse impact on the quality of life and prognos...
Editorial: Advancing antibiotic candidates for eradication of persistent bacterial infections [0.03%]
编者按：抗生素候选药物的发展以根除顽固细菌感染为目标
Laurent A Bekale,Jessica Amber Jennings,Xilin Zhao
Laurent A Bekale
Acetylshikonin mitigates diet-induced MASLD by targeting PPARγ-mediated metabolic dysfunction [0.03%]
阿魏酸茋苷通过靶向PPARγ介导的代谢功能障碍缓解饮食诱导的MASLD
Ling Ou,Qian Du,Jiayang Liu et al.
Ling Ou et al.
Introduction: The liver, as the central metabolic hub of the body, is highly susceptible to diet-induced injury. The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the...
Natural compounds as multitarget agents in Alzheimer's diseases: evidence from in vivo and in vitro models [0.03%]
阿尔茨海默病的天然多靶向制剂：活体和离体模型证据
Vicko Suswidiantoro,Kim San Tang,Khalid Rahman et al.
Vicko Suswidiantoro et al.
Introduction: Alzheimer's disease (AD), the most common cause of dementia, is marked by a gradual decline in cognitive function driven by amyloid-β (Aβ) deposition, tau hyperphosphorylation, synaptic failure, neuroinfla...
Risk assessment of drug-associated miscarriage using XGBoost and SHAP explainability: a real-world pharmacovigilance analysis based on the FAERS database [0.03%]
基于FAERS数据库的药物致流产风险评估及Xgboost-Shap可解释性研究
Sen Lin,Lanyue Ma,Ruiqi Zhao et al.
Sen Lin et al.
Background: Miscarriage is a common and serious adverse pregnancy outcome. Assessing drug-associated miscarriage risk is essential for medication safety in pregnancy. Using the FDA Adverse Event Reporting System this stud...
Drug-associated insomnia and sex-specific disproportionality in the FDA adverse event reporting system (2019-Q1 2025) [0.03%]
FDA不良事件报告系统中的失眠及相关药物的性别差异（2019年第一季度-2025年）
Hao Wen,Yuchuan Shen,Hai Li et al.
Hao Wen et al.
Insomnia is a frequent and clinically relevant adverse drug reaction that can impair quality of life, treatment adherence and long-term outcomes. Evidence on drug-associated insomnia has largely been derived from selected clinical trial pop...
Prospective evaluation of medication-related problems and pharmacist interventions in liver transplant recipients [0.03%]
肝移植受者的药物相关问题及药剂师干预的前瞻性评估
Sena Güzel Karahan,Mefküre Durmuş,Ahmet Çakır et al.
Sena Güzel Karahan et al.
Background: Medication-related problems (MRPs) are a common patient safety issue among hospitalized individuals, often associated with reduced quality of life, increased healthcare costs, and higher mortality. Due to the ...
TAAR1-mediated pathways regulating nigrostriatal function and the discovery and pharmacological characterization of a novel TAAR1 agonist, Selutaront [0.03%]
TAAR1介导的通路调节黑质纹状体功能及新型TAAR1激动剂Selutaront的发现和药理学特征研究
Jianzhao Zhang,Xuan Deng,Jiawei Lv et al.
Jianzhao Zhang et al.
Introduction: Schizophrenia is a severe neurodevelopmental disorder with limited treatment options. Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target, yet its downstream signaling mec...